Centrus Fair Value Edges Lower: Near $177, LEU Still Looks Priced for Perfection

Centrus's latest quarter sharpened, but did not settle, the valuation debate

Fair value is near the market price, which still leaves little room for mistakes

Centrus's fair value is edging lower again and now sits near Market price $177.0, essentially equal to the stock's Market Cap: $3.5 Bil. Even after the pullback, that setup still looks like a stock pricing in a lot of execution success.

That matters because the latest quarter did not end the debate. It reframed it. Centrus delivered Q2 revenue of $176.1 million, showed commercial momentum, and added high-profile strategic wins including a $900 million High-Assay, Low-Enriched Uranium (HALEU) Enrichment award contract with U.S. Department of Energy and Grew contingent Low-Enriched Uranium (LEU) and HALEU enrichment backlog to $3.0 billion. But the market is still asking whether that strategic importance should be fully reflected in today's share price.

Sentiment remains split between long-term scarcity and near-term valuation discipline

The bear case starts with valuation discipline. Recent coverage has highlighted analysts sharply lowered consensus EPS estimates and now expect year over year declines in earnings and revenue for the June 2026 quarter, while also noting the stock was down 5.87% over the past day and 24.30% over the past 90 days. That does not prove Centrus is cheap or expensive on its own, but it does show investors remain sensitive to expectation cuts and premium multiples.

The bull case does not require dismissing that concern. It argues the premium exists because Centrus offers exposed to U.S. HALEU production, a company with Selected Geiger Brothers as construction contractor for major uranium enrichment plant expansion and other assets that could become more important if domestic HALEU supply remains tight.

My view is straightforward: Centrus's strategic value looks real, but the equity still appears expensive enough that even modest operational or timing slippage could pressure the stock.

Why the bullish case still has support

The core argument rests on current revenue and future enrichment optionality

The bullish case is not just a policy story. Bulls can point to a business that generated Q2 revenue of $176.1 million, up 14% year on year, while also advancing the infrastructure and contracts that could matter more if HALEU becomes a true bottleneck.

What bulls are really watching is not just today's earnings power, but whether Centrus is becoming a scarce node in the U.S. nuclear fuel chain. That includes enrichment expansion, DOE support, and commercial milestones that would matter more in a tighter supply environment than in a story-driven rally.

Why the bearish case still matters

A stronger quarter does not automatically justify a premium multiple

The bearish argument is not that Centrus lacks relevance. It is that the current earnings profile still leaves little room for another reset in expectations.

That is the real split in this stock. Bulls are right about strategic value. Bears are right that, so far, the quarter improved the narrative more than it resolved the valuation debate.